Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 68
Filter
1.
CPT Pharmacometrics Syst Pharmacol ; 3: e128, 2014 Aug 06.
Article in English | MEDLINE | ID: mdl-25098530

ABSTRACT

Mouse cancer models have provided critical insights into tumor biology; however, clinical translation of these findings has been challenging. This perspective posits that factors impacting on successful translation start with limitations in capturing human cancer pathophysiology and end with challenges in generating robust translatable preclinical end points. A comprehensive approach that considers clinically relevant mouse models with both an integrated biomarker strategy and a complementary modeling and simulation effort will strengthen the current oncology drug development paradigm.

2.
Transplant Proc ; 42(8): 3273-6, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20970670

ABSTRACT

One hundred two recipients of hematopoietic stem cell transplants (HSCTs) 45, from siblings and 57 from matched unrelated donors, were followed for cytomegalovirus (CMV), human herpes virus (HHV) 6, and Epstein-Barr Virus (EBV) reactivation by quantitative polymerase chain reaction in the context of immunologic reconstitution and posttransplantation complications. CMV, EBV, and HHV6 DNA copies (>100 copies/10(5) cells) were detected in 34%, 27%, and 26% of patients, respectively. The presence of 100 copies of EBV or CMV was associated with posttransplant complications: 29/66 versus 6/36 (P<.01) or 24/66 versus 4/36 (P=.01). CMV reactivation was more frequent among patients with acute graft-versus-host disease grade≥I: 17/35 versus 18/67 (P<.05). Older patient age of adults>16 year (2/16 versus 33/86; P<.05) and, to a lesser extent, CMV IgG positivity before HSCT (34/84 versus 1/10; P=.08) or an HLA-mismatched graft (9/16 versus 26/86; P=.08) constituted risk factors for CMV reactivation, which resulted in a higher rate of bacterial pneumonia (7/11 versus 28/91; P=.04). EBV reactivation risk was associated with donor EBV IgG seropositivity (28/84 versus 0/10; P=.03) and donor female gender (18/47 versus 10/55; P=.03). In contrast to EBV and CMV, EBV reactivation itself was associated with encephalitis (5/8 versus 23/94; P=.013), which was also seen as a trend among HHV6 reactivations (8/8 versus 46/94; P=.08). Multivariate analysis demonstrated that these factors play independent roles in the reactivation of the investigated herpes viruses.


Subject(s)
Cytomegalovirus/physiology , Hematopoietic Stem Cell Transplantation/adverse effects , Herpesvirus 4, Human/physiology , Herpesvirus 6, Human/physiology , Virus Activation , Cytomegalovirus/genetics , DNA, Viral/genetics , Female , Herpesvirus 4, Human/genetics , Herpesvirus 6, Human/genetics , Humans , Male , Polymerase Chain Reaction , Risk Factors , Treatment Outcome
3.
Bone Marrow Transplant ; 40(10): 983-8, 2007 Nov.
Article in English | MEDLINE | ID: mdl-17846600

ABSTRACT

In this multicenter study, we assessed the use of palifermin (recombinant human-keratinocyte growth factor 1) in the prevention of oral mucositis (OM) and acute GvHD (aGvHD) induced by a hematopoietic stem cell transplant (HSCT). Fifty-three patients with hematological diseases received three doses of palifermin (60 mug/kg once daily i.v.) pre- and post-conditioning regimens (total six doses). A retrospective control group of 53 transplant patients received no palifermin. There was a significant reduction in the incidence of OM of WHO (World Health Organization) grades 1-4 (58 vs 94%, P<0.001), 3-4 (13 vs 43%, P<0.001) and the median duration of OM (4 vs 9 days, P<0.001) in the palifermin group compared to the control group. The incidence of analgesics (32 vs 75.5%, P<0.001), opioid analgesics (24 vs 64%, P<0.001) and total parenteral nutrition (11 vs 45%, P<0.001) was also significantly reduced. The analysis of distribution of affected organs revealed that aGvHD was less prevalent in the palifermin group (P=0.036). There was no significant difference in the onset of any OM after HSCT, time to engraftment and length of hospitalization between groups. The drug was generally well tolerated and safe. Our results suggest that the use of palifermin reduces OM and probably aGvHD after HSCT, but a randomized trial is needed.


Subject(s)
Fibroblast Growth Factor 7/therapeutic use , Graft vs Host Disease/prevention & control , Hematologic Diseases/therapy , Hematopoietic Stem Cell Transplantation , Stomatitis/prevention & control , Adolescent , Adult , Female , Fibroblast Growth Factor 7/adverse effects , Hematopoietic Stem Cell Transplantation/adverse effects , Humans , Male , Middle Aged , Retrospective Studies
4.
Cancer Gene Ther ; 13(3): 242-52, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16179928

ABSTRACT

An adenovirus (Adv) retaining normal E1A but lacking the 55 kDa E1B protein replicates preferentially in TP53-deficient cancer cells including pancreatic cancer cell lines, resulting in the oncolysis of the tumor. When tumor cells are exposed to hypoxia, hypoxia-inducible factor-1alpha (HIF-1alpha) is stabilized and activated to promote the transcription of several genes such as vascular endothelial growth factor (VEGF), but in the presence of E1A hypoxia-induced VEGF m-RNA synthesis is inhibited by E1A binding to p300. In this study, we demonstrated that the cancer cells infected with a mutant Adv in which the p300 binding site in E1A was partially deleted induced a higher expression level of VEGF as compared to those of Adv with normal E1A. An immunoprecipitation study for E1A confirmed that mutant E1A had a reduced binding capacity for p300. Although the expressions of HIF-1alpha m-RNA were almost the same in both cancer cells infected with the mutant Adv and those with the wild Adv, the amount of HIF-1alpha protein in cancer cells infected with the wild E1A Adv was lower than in those infected with the mutant E1A type Adv. In vivo, in contrast to the angiogenesis treated with mutant E1A, wild-E1A inhibited tumor angiogenesis significantly. These results suggested that E1A suppressed the production of VEGF and inhibited tumor angiogenesis by binding with p300, resulting in the inhibition of the HIF-1alpha-mediated transcription of genes through binding to HRE. This study demonstrates, for the first time, the effect of an oncolytic replication-competent Adv in inhibiting tumor angiogenesis.


Subject(s)
Adenoviridae/physiology , Adenovirus E1A Proteins/genetics , Neovascularization, Pathologic/prevention & control , Oncolytic Virotherapy , Pancreatic Neoplasms/blood supply , Virus Replication , Animals , Binding Sites , Cell Hypoxia , Humans , Hypoxia-Inducible Factor 1, alpha Subunit/metabolism , Male , Mice , Mice, SCID , Pancreatic Neoplasms/genetics , Pancreatic Neoplasms/metabolism , Promoter Regions, Genetic , RNA, Messenger , Transcription, Genetic , Transfection , Tumor Cells, Cultured , Vascular Endothelial Growth Factor A/metabolism , p300-CBP Transcription Factors/metabolism
5.
Inflamm Res ; 53 Suppl 2: S164-8, 2004 Aug.
Article in English | MEDLINE | ID: mdl-15338070

ABSTRACT

OBJECTIVE: Histamine release may cause anaphylactoid reactions. However, during anaesthesia and surgery especially cardiovascular effects may not be regarded as histamine-related. Therefore, we adapted the classical concept of histamine release reactions to the perioperative situation and validated the new paradigm. METHODS: Elevated plasma histamine (diagnostic gold standard) was correlated to potentially related intraoperative signs and symptoms. The validity, repeatability and sensitivity of the 'gold standard' was tested by ROC analysis in volunteers, who also received H1-/H2-histamine antagonists. Additionally, a dose-response relationship was determined in dogs using the histamine releaser compound 48/80. RESULTS: The 'gold standard' had a sensitivity of 96% (90%-100%) and a specificity of 93% (85%-100%). The reproducibility was proven by repeated injections of histamine. Skin reactions, tachycardia and hypertension were identified as histamine-related diagnostic variables. A dose-response curve of plasma histamine release was created. CONCLUSIONS: The defined 'gold standard' is valid for the diagnosis of histamine-related reactions during anaesthesia and surgery. It may help to identify patients, who could benefit from pre-anaesthetic antihistamine prophylaxis.


Subject(s)
Diagnostic Tests, Routine/standards , Histamine/pharmacology , Hypersensitivity/diagnosis , Animals , Decision Making , Dose-Response Relationship, Drug , Histamine/administration & dosage , Histamine/blood , Histamine H1 Antagonists/pharmacology , Histamine H2 Antagonists/pharmacology , Humans , Hypersensitivity/classification , Injections , Interviews as Topic , Perioperative Care , ROC Curve , Reproducibility of Results , Sensitivity and Specificity
7.
Anaesthesiol Reanim ; 28(4): 97-103, 2003.
Article in German | MEDLINE | ID: mdl-14528656

ABSTRACT

Mesenteric traction syndrome occurs during abdominal surgery and is described as sudden tachycardia, hypotension and flush. Among other etiological factors, eventeration or mesenteric traction of the small intestine may cause histamine release from mesenteric mast cells. Therefore, our hypothesis was that mesenteric traction syndrome could be positively influenced by prophylactic administration of H1- and and H2-antihistamines. Seventeen male patients (ASA groups III-V, 48-78 years old) were investigated in a randomised double blind study during elective abdominal aortic aneurysm (AAA) repair; which, in our opinion, is one of the most standardised surgical procedures. Eight patients had pre-anaesthetic prophylaxis with 0.1 mg/kg BW dimetindene (H1-receptor antagonist) plus 5 mg/kg BW cimetidine (H2-receptor antagonist) diluted with 100 ml 0.9% NaCl, while 9 patients received a placebo (100 ml 0.9% NaCl). Anaesthesia and invasive haemodynamic monitoring were standardised in all patients. Haemodynamic parameters, plasma histamine concentrations and clinical symptoms were determined one min after skin incision (HS), and 5 and 20 min after mesenteric traction (5' EV and 20' EV). Statistical analyses were performed using the Student's t-test, the Mann-Whitney-U-test for continuous data and Chi2-test for incidences. The incidence of histamine release was 55.5% (5/9) in the placebo group vs. 37.5% (3/8) in the antihistamine group (p > 0.05, Chi2-test). Plasma histamine levels (mean +/- SD) were higher in the placebo group than in the antihistamine group at 5 and 20 min after mesenteric traction, but there was no statistical significance. Arrhythmias were significantly more frequent in the placebo group (6 times) than in the antihistamine group (none) (p = 0.005 Chi2-test). Systolic blood pressure was not statistically different between the groups (e.g. 5 min after mesenteric traction, mean +/- SD; placebo 111 +/- 20 mm Hg vs. antihistamines 119 +/- 35 mm Hg). In the placebo group, however, the haemodynamics only stabilised 5 min after mesenteric traction when anaesthetic gas concentration was repeatedly reduced and vasopressor/volume administration was increased (placebo group = 20 times vs. antihistamine group = 8 times (p = 0.001, Chi2-test). From these results we conclude that prophylactic administration of antihistamines reduces in particular the incidence of arrhythmias and the number of stabilising measures during mesenteric traction. Prophylaxis with H1- and H2-antihistamines may therefore be of perioperative benefit and should be considered in AAA surgery.


Subject(s)
Aortic Aneurysm, Abdominal/surgery , Histamine Antagonists/therapeutic use , Histamine Release/physiology , Intraoperative Complications/prevention & control , Intraoperative Complications/physiopathology , Splanchnic Circulation/physiology , Traction/adverse effects , Vascular Surgical Procedures , Aged , Double-Blind Method , Hemodynamics/physiology , Histamine Release/drug effects , Humans , Male , Mast Cells/drug effects , Mast Cells/metabolism , Middle Aged , Splanchnic Circulation/drug effects
8.
Inflamm Res ; 52(10): 408-16, 2003 Oct.
Article in English | MEDLINE | ID: mdl-14520516

ABSTRACT

OBJECTIVE: The perioperative use of colloidal plasma substitutes is still under discussion. We therefore conducted a prospective randomised study with three commonly used plasma substitutes to examine their histamine releasing effects in 21 volunteers. MATERIAL OR SUBJETS: 21 male volunteers were enrolled in this prospective, randomised, controlled clinical study. Endpoints were the incidence of early and late histamine release and the time course of the release kinetics. Normovolemic hemodilution technique was used with hydroxyethyl starch (n = 6), human albumin (n = 6) and polygeline (n = 9). Measurement and observation period was 240 min after the start of the plasma substitute infusion. Heart rate, blood pressure, SaO(2), clinical symptoms/signs and plasma histamine were measured during the observation period. RESULTS: The incidence of histamine release over the whole observation period in all three groups was 100%. Histamine release occurred frequently in all three groups until 30 min (50%-78%) and up to 240 min (late release reaction: 67%-83%) after the start of infusion. Surprisingly even hydroxyethyl starch, which is regarded as a generally safe and effective plasma substitute, caused high incidences of late histamine release (67%). Histamine release is a well known side effect of polygeline and - to a lesser extent - also of albumin, but was a novel finding for hydroxyethyl starch. CONCLUSIONS: We demonstrated for the first time histamine releasing effects of hydroxyethyl starch over a long period of time after administration. This perioperatively and for intensive care possibly relevant finding should make clinicians aware of late side effects not yet connected with the clinical use of these colloidal plasma substitutes.


Subject(s)
Histamine Release/drug effects , Hydroxyethyl Starch Derivatives/pharmacology , Plasma Substitutes/pharmacology , Polygeline/pharmacology , Serum Albumin/pharmacology , Adult , Aged , Blood Pressure/drug effects , Double-Blind Method , Heart Rate/drug effects , Hemodilution/adverse effects , Hemodynamics/drug effects , Histamine/blood , Humans , Hydroxyethyl Starch Derivatives/adverse effects , Male , Middle Aged , Plasma Substitutes/adverse effects , Polygeline/adverse effects
10.
Inflamm Res ; 51(10): 495-9, 2002 Oct.
Article in English | MEDLINE | ID: mdl-12477078

ABSTRACT

OBJECTIVE AND DESIGN: Mesenteric traction syndrome is described as sudden tachycardia, hypotension and flush. Among other etiological factors eventeration or mesenteric traction of the small intestine may cause histamine release from mesenteric mast cells. We hypothesized that mesenteric traction syndrome may be positively influenced by prophylactic antihistamine administration. METHODS: Male patients (n = 17, ASA groups III-IV, 48-78 years old) were investigated in a randomised double blind study during elective abdominal aortic aneurysm (AAA) repair. Eight patients had pre-anaesthetic prophylaxis with dimetindene (H1-receptor antagonist) plus cimetidine (H2-receptor antagonist), 9 patients received placebo. Anaesthesia and invasive haemodynamic monitoring were standardised in all patients. Haemodynamic parameters, plasma histamine concentrations and clinical symptoms were determined 1 min after skin incision, as well as 5 and 20 min after mesenteric traction. Statistical analyses were performed using the Student's t-test, Chi2-test for incidences and Mann-Whitney-U-test for continuous data. RESULTS: The incidence of histamine release was 55.5% (5/9) in the placebo group vs. 37.5% (3/8) in the antihistamine group (p > 0.05, Chi2-test). Plasma histamine levels (mean +/- SD) were higher in the placebo group than in the antihistamine group at 5 and 20 min after mesenteric traction but the difference did not reach statistical significance. Arrhythmias were significantly more frequent in the placebo group (6 times) than in the antihistamine group (none) (p = 0.005 Chi2-test). Systolic blood pressure was not statistically different between groups (e.g. 5 min after mesenteric traction, mean +/- SD; placebo 111 +/- 20 mm Hg vs. antihistamines 119 +/- 35 mm Hg). However, in the placebo group the haemodynamics only stabilised 5 min after mesenteric traction when anaesthetic gas concentration was repeatedly reduced and vasopressor/volume administration was increased (placebo-group = 20 times/antihistamine-group = 8 times, p = 0.001, t-test). CONCLUSION: Prophylactic administration of antihistamines reduced the incidence of histamine release as well as the incidence of arrhythmias and the amount of stabilising measures during mesenteric traction. Prophylaxis with H1 and H2 antihistamines may be of perioperative benefit and should therefore be considered in AAA-surgery.


Subject(s)
Flushing/metabolism , Histamine H1 Antagonists/pharmacology , Histamine H2 Antagonists/pharmacology , Histamine Release/physiology , Hypotension/metabolism , Intraoperative Complications/metabolism , Splanchnic Circulation/physiology , Tachycardia/metabolism , Aortic Aneurysm, Abdominal/surgery , Blood Pressure/drug effects , Cardiac Output/physiology , Cimetidine/pharmacology , Dimethindene/pharmacology , Double-Blind Method , Flushing/physiopathology , Heart Rate/physiology , Histamine Release/drug effects , Humans , Hypotension/physiopathology , Intraoperative Complications/physiopathology , Laparoscopy , Male , Prospective Studies , Syndrome , Tachycardia/physiopathology , Vascular Surgical Procedures
11.
Br J Cancer ; 86(3): 490-6, 2002 Feb 01.
Article in English | MEDLINE | ID: mdl-11875720

ABSTRACT

The brain-specific angiogenesis inhibitor 1 gene has been isolated in an attempt to find fragments with p53 "functional" binding sites. As reported herein and by others, brain-specific angiogenesis inhibitor 1 expression is present in some normal tissues, but is reduced or lost in tumour tissues. Such data and its particular structure prompted the hypothesis that brain-specific angiogenesis inhibitor 1 may act as a mediator in the local angiogenesis balance. We herein demonstrate that brain-specific angiogenesis inhibitor 1 over-expression suppresses tumour angiogenesis, delaying significantly the human tumour growth in immunodeficient mice. The inhibitory effect of brain-specific angiogenesis inhibitor 1 was documented using our intravital microscopy system, strongly implicating brain-specific angiogenesis inhibitor 1 as a mediator in the control of tumour angiogenesis. In contrast, in vitro tumour cell proliferation was not inhibited by brain-specific angiogenesis inhibitor 1 transfection, whereas some level of cytotoxicity was assessed for endothelial cells. Immunohistochemical analysis of tumour samples confirmed a reduction in the microvessel density index in brain-specific angiogenesis inhibitor 1-overexpressing tumours. At messenger level, moderate changes could be detected, involving the down-regulation of vascular endothelial growth factor and collagenase-1 expression. Furthermore, brain-specific angiogenesis inhibitor 1 expression that was lost in a selection of human cancer cell lines could be restored by wild-type p53 adenoviral transfection. Brain-specific angiogenesis inhibitor 1 should be considered for gene therapy and development of efficient drugs based on endogenous antiangiogenic molecules.


Subject(s)
Adenocarcinoma/pathology , Angiogenic Proteins , Genes, p53 , Neovascularization, Pathologic/prevention & control , Pancreatic Neoplasms/pathology , Proteins/genetics , Adenocarcinoma/blood supply , Angiogenesis Inhibitors , Animals , Cell Division/drug effects , Humans , Mice , Mice, SCID , Pancreatic Neoplasms/blood supply , Receptors, G-Protein-Coupled , Reverse Transcriptase Polymerase Chain Reaction , Transfection , Transplantation, Heterologous , Tumor Cells, Cultured
12.
Br J Cancer ; 85(3): 431-8, 2001 Aug 03.
Article in English | MEDLINE | ID: mdl-11487277

ABSTRACT

The mechanism of metastasis formation remains still largely unknown. Many studies underline the importance and complexity of the initial arrest of the circulating tumour cells in the target organ, a key stage in metastasis occurrence. In our study, we evaluated by visual means the metastasis formation using an in vivo microscopy system in a murine model. Moreover, we investigated the involvement of P-selectin in these processes using immunohistochemistry and P-selectin knockout mice. The present study offers direct evidence of distinct pathways for tumour metastasis formation by a lymphoma cell - EL-4 and a solid tumour cell - C26. Off-line analysis of the images and histological data confirmed that mechanical entrapment of the solid tumour cell, which had a bigger diameter than that of the liver sinusoids, promoted metastasis without any detectable involvement of adhesion molecules. On the other hand, we observed that lymphoma cells, in spite of their smaller diameter as compared to the sinusoids, promoted liver metastasis as well, but with the essential participation in their arrest of P-selectin, indicating an adhesion molecule-mediated pathway.


Subject(s)
Adenocarcinoma/metabolism , Colonic Neoplasms/metabolism , Liver Neoplasms/metabolism , Lymphoma/metabolism , Neoplastic Cells, Circulating/metabolism , P-Selectin/physiology , Adenocarcinoma/pathology , Animals , Colonic Neoplasms/pathology , Flow Cytometry , Immunoenzyme Techniques , Immunoglobulin G/immunology , Lymphatic Metastasis/pathology , Lymphoma/pathology , Male , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Mice, Knockout , Neoplasm Transplantation , Neoplastic Cells, Circulating/pathology , P-Selectin/metabolism , Tumor Cells, Cultured
13.
Inflamm Res ; 50(5): 233-48, 2001 May.
Article in English | MEDLINE | ID: mdl-11409486

ABSTRACT

GENERAL DESIGN: Presentation of a new type of a study protocol for evaluation of the effectiveness of an immune modifier (rhG-CSF, filgrastim): prevention of postoperative infectious complications and of sub-optimal recovery from operation in patients with colorectal cancer and increased preoperative risk (ASA 3 and 4). A randomised, placebo controlled, double-blinded, single-centre study is performed at an University Hospital (n = 40 patients for each group). This part presents the course of the individual patient and a complication algorithm for the management of anastomotic leakage and quality management. OBJECTIVE: In part three of the protocol, the three major sections include: The course of the individual patient using a comprehensive graphic display, including the perioperative period, hospital stay and post discharge outcome. A center based clinical practice guideline for the management of the most important postoperative complication--anastomotic leakage--including evidence based support for each step of the algorithm. Data management, ethics and organisational structure. CONCLUSIONS: Future studies with immune modifiers will also fail if not better structured (reduction of variance) to achieve uniform patient management in a complex clinical scenario. This new type of a single-centre trial aims to reduce the gap between animal experiments and clinical trials or--if it fails--at least demonstrates new ways for explaining the failures.


Subject(s)
Algorithms , Colorectal Neoplasms/surgery , Controlled Clinical Trials as Topic , Granulocyte Colony-Stimulating Factor/therapeutic use , Postoperative Complications/prevention & control , Research Design , Anesthesia , Evidence-Based Medicine , Granulocyte Colony-Stimulating Factor/administration & dosage , Granulocyte Colony-Stimulating Factor/adverse effects , Humans , Quality Control , Recombinant Proteins , Risk
14.
Biochemistry ; 40(6): 1741-8, 2001 Feb 13.
Article in English | MEDLINE | ID: mdl-11327835

ABSTRACT

Histidine 64 in human carbonic anhydrase II (HCA II) functions in the catalytic pathway of CO(2) hydration as a shuttle to transfer protons between the zinc-bound water and bulk water. Catalysis of the exchange of (18)O between CO(2) and water, measured by mass spectrometry, is dependent on this proton transfer and was decreased more than 10-fold for H64A HCA II compared with wild-type HCA II. The loss of catalytic activity of H64A HCA II could be rescued by 4-methylimidazole (4-MI), an exogenous proton donor, in a saturable process with a maximum activity of 40% of wild-type HCA II. The crystal structure of the rescued complex at 1.6 A resolution shows 4-MI bound in the active-site cavity of H64A HCA II, through pi stacking interactions with Trp 5 and H-bonding interactions with water molecules. In this location, 4-MI is about 12 A from the zinc and approximates the observed "out" position of His 64 in the structure of the wild-type enzyme. 4-MI appears to compensate for the absence of His 64 and rescues the catalytic activity of the H64A HCA II mutant. This result strongly suggests that the out conformation of His 64 is effective in the transfer of protons between the zinc-bound solvent molecule and solution.


Subject(s)
Carbonic Anhydrases/chemistry , Carbonic Anhydrases/metabolism , Protons , Alanine/chemistry , Alanine/genetics , Binding Sites/genetics , Carbon Dioxide/chemistry , Carbonic Anhydrases/genetics , Catalysis , Crystallography, X-Ray , Enzyme Activation/drug effects , Histidine/chemistry , Histidine/genetics , Humans , Imidazoles/chemistry , Imidazoles/pharmacology , Kinetics , Oxygen Isotopes , Recombinant Proteins/chemistry , Recombinant Proteins/metabolism , Structure-Activity Relationship , Water , Zinc/chemistry
15.
Percept Mot Skills ; 90(2): 415-22, 2000 Apr.
Article in English | MEDLINE | ID: mdl-10833733

ABSTRACT

The frequency of extensions and flexions of the arms of 12 men and 12 women (ages 20-30 years) responding to a neutral tone or to an electric shock was recorded. Subjects had to choose between pushing or pulling a lever upon receipt of an acoustic signal which was paired or unpaired with an electric shock. They were instructed to perform either long duration movements, allowing for on-line control of the execution, or short duration movements with prior specification of amplitude. Regardless of duration of movements, the aversive signal increased the frequency of extensions and intraindividual variability of choices of the men but decreased the frequency of extensions and intraindividual variability of choices of the women. These findings show that stimuli such as pain or fear automatically elicit patterns of terminal motor states corresponding to fight or flight, initiating processes of preparation of spatially oriented movements which are automatic and sex-typed and impair the use of the terminal cues for simultaneous preprogrammed voluntary movements.


Subject(s)
Arm/physiology , Cognition/physiology , Electroshock , Motor Activity/physiology , Posture/physiology , Acoustic Stimulation , Adult , Agonistic Behavior/physiology , Biomechanical Phenomena , Fear/physiology , Female , Humans , Male , Motor Cortex/physiology , Muscle Contraction/physiology , Pain/psychology , Reaction Time/physiology , Sex Factors
16.
Pancreas ; 20(3): 227-33, 2000 Apr.
Article in English | MEDLINE | ID: mdl-10766447

ABSTRACT

Interleukin 12 (IL-12) is a heterodimeric cytokine that exerts a potent antitumor effect through its pleiotropic actions. It was recently reported that IL-12 has also a potent antiangiogenic effect through the induction of IFN-gamma, which triggers the production of chemokines such as IP-10 that has been shown to have antiangiogenesis properties. In this study we transfected the IL-12 gene into a human pancreatic adenocarcinoma cell line (PK-1). PK-1 cells transfected with the green fluorescence protein (gfp) gene were used as positive controls. The in vitro growth curve and in vivo tumor growth of transfectants (IL-12/PK-1 and gfp/PK-1) were compared with those of parental cells. The SCID mice used in this study were administered antiasialo GM-1 Ab (100 microg, i.p., twice weekly) to deplete the remaining immunoeffector cells, NK cells. Using a skinfold chamber model, we observed and recorded tumor angiogenesis by intravital microscopy. In vitro growth of IL-12/PK-1 and gfp/PK-1 cells was not different from that of wild-type PK-1 cells (wt/PK-1). However, IL-12 transfected PK-1 cells did not develop into tumors as did the wt/PK-1 cells after subcutaneous inoculation in antiasialo GM-1 Ab administered SCID mice. The growth of IL-12/PK-1 tumors was restored in mice treated with anti-IL-12 antibody. We found that IL-12/PK-1, in contrast to gfp/PK-1 and wt/PK-1, failed to initiate an angiogenic response, as observed in the skinfold chamber model. These results indicate that the antiangiogenesis effect of IL-12 alone, without immune system involvement, is sufficient to block the growth of human pancreatic cancer.


Subject(s)
Interleukin-12/physiology , Neovascularization, Pathologic , Pancreatic Neoplasms/blood supply , Adenocarcinoma/blood supply , Adenocarcinoma/pathology , Animals , Humans , Interleukin-12/genetics , Interleukin-12/metabolism , Mice , Mice, SCID , Neoplasm Transplantation , Neovascularization, Pathologic/prevention & control , Pancreatic Neoplasms/pathology , Transfection , Tumor Cells, Cultured
17.
Psychol Rep ; 86(1): 232-42, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10778276

ABSTRACT

The effects of presentation of an aversive stimulus and simultaneous failure on a bogus intelligence test upon a subject's aggressive reactions were studied. The subject's fist clenching was used as an indicator of aggression. Four conditions, generated by the combinations of two kinds of stimulus delivered to the subjects (aversive or nonaversive) and two outcomes of the task (failure or success), were investigated. 20 female and 20 male students (ages: 17-34 years) were instructed, upon the reception of an aversive or nonaversive acoustic signal, to press with the right hand a device that displayed a slide. Each slide presented an item from an intelligence test, to which the subjects were either allowed to answer successfully (success) or not (failure). Failure increased the subject's autonomic arousal, as measured by photoplethysmographic sensors, in all stimulation conditions, but only the condition with aversive stimulation increased the speed of clenching. This was interpreted as indicating subject's tendencies to aggression. These results are discussed in relation to the effects of frustration.


Subject(s)
Achievement , Aggression/psychology , Arousal , Internal-External Control , Motivation , Acoustic Stimulation , Adolescent , Adult , Female , Frustration , Humans , Individuality , Male , Problem Solving
18.
Cancer Res ; 60(4): 1111-6, 2000 Feb 15.
Article in English | MEDLINE | ID: mdl-10706132

ABSTRACT

As an antitumor agent, interleukin-12 (IL-12) has been revealed to be a key regulator of the immune response, particularly that involving CTL and natural killer (NK) cells. We report herein the antiangiogenesis effect of IL-12 on human as well as murine tumors in NK-depleted severe-combined immunodeficient mice using fibroblasts genetically engineered to secrete this cytokine. Although the in vitro growth of tumor cells was not affected by the presence of IL-12, coinoculation of IL-12-secreting fibroblasts strongly inhibited tumor growth in immunodeficient mice. The neovascularization surrounding the tumor was remarkably inhibited in the area in which the IL-12-secreting fibroblasts were implanted, resulting in the suppression of tumor growth. Lectin staining in tumor sample sections also showed a significant reduction in the number of vessels. The RNA expression of IFN-gamma and its inducible antiangiogenic chemokine IFN gamma-inducible protein 10 was stimulated in endothelial cells cultured with IL-12. It was also found that IL-12 down-regulated the expression of the endothelial cell mitogens vascular endothelial growth factor and basic fibroblast growth factor. The antitumor effects of IL-12 were accompanied by interesting histological changes consisting of a high degree of keratinization and apoptosis and a decrease in the proliferation rate of human tumors and extensive necrosis in the murine ones.


Subject(s)
Angiogenesis Inhibitors/pharmacology , Interleukin-12/pharmacology , Neoplasms, Experimental/blood supply , Neovascularization, Pathologic/prevention & control , 3T3 Cells , Animals , Cytokines/biosynthesis , Cytokines/genetics , Humans , Male , Mice , Mice, SCID , Tumor Cells, Cultured
19.
Hum Gene Ther ; 11(2): 223-35, 2000 Jan 20.
Article in English | MEDLINE | ID: mdl-10680837

ABSTRACT

Pancreatic cancer has a poor prognosis even when surgical treatment can be accomplished. Studies have demonstrated that pancreatic cancer is associated with various genetic abnormalities in oncogenes and tumor suppressor genes including p53. New therapeutic approaches for pancreatic cancer can be developed by targeting these genetic alterations. Adenovirus (Adv) lacking the 55-kDa E1B protein (E1B55K) replicates preferentially in p53-deficient cancer cells. We constructed E1B55K-deleted Adv (AxE1AdB), and studied its replication and cytopathic effect on pancreatic cancer cells. AxE1AdB replicated in and caused cell death of the p53-deficient pancreatic cancer cell lines tested (e.g., PANC-1, MIAPaCa-2, SU.86.86, BxPC-3, and PK-1). To enhance its therapeutic effect, we examined the combination of coinfecting this restricted replication-competent adenovirus (RRCA) with other Adv. Coinfection of E1-deficient Adv expressing the reporter lacZ gene (AxCAlacZ) together with AxE1AdB resulted in the replication of both viruses and a marked increase in reporter gene expression. PANC-1 cells coinfected with AxE1AdB and the Adv for human IL-2 (AxCAhIL2), produced 110 times more IL-2 than those infected with AxCAhIL2 alone. Similarly, coinfection of AxE1AdB and Adv for human IL-12 augmented the IL-12 production by 370-fold. Injecting AxE1AdB into the PANC-1 tumor of severe combined immunodeficient mice (SCID mice) resulted in marked reduction of the volume of the tumor. Moreover, injecting AxE1AdB with AxCAhIL2 into the PANC-1 tumor resulted in complete regression of the established tumors. These data suggest that RRCA, which augments the antitumor effect of a viral transgene (i.e., cytokines), may be a powerful tool for treating p53-deficient pancreatic cancer.


Subject(s)
Adenoviridae/genetics , Adenovirus E1B Proteins/genetics , Genetic Therapy/methods , Pancreatic Neoplasms/therapy , Animals , Cell Count , Cell Division/genetics , Defective Viruses/genetics , Genome, Viral , Humans , Interleukin-12/biosynthesis , Interleukin-12/genetics , Interleukin-2/genetics , Mice , Mice, SCID , Mutation , Neoplasm Transplantation , Plasmids , Recombination, Genetic , Time Factors , Tumor Cells, Cultured , Tumor Suppressor Protein p53/genetics , Virus Replication/genetics , beta-Galactosidase/metabolism
20.
J Am Acad Child Adolesc Psychiatry ; 38(3): 250-5, 1999 Mar.
Article in English | MEDLINE | ID: mdl-10087685

ABSTRACT

OBJECTIVE: To determine prospectively whether parental receipt of injury prevention education is associated with new action limiting access to lethal means and if so, what action was taken for which means. METHOD: Prospective follow-up of 103 adults whose children made an emergency department visit for mental health assessment or treatment. Record review assessed whether hospital staff provided injury prevention education. Logistic regression was used to determine the likelihood of new caretaker action limiting access to the following potentially lethal means: firearms, alcohol, prescription medications, and over-the-counter medications. RESULTS: Significant associations were found between exposure to injury prevention education and action to limit access (adjusted odds ratio = 3.6, 95% confidence interval = 1.1-12.1, p = .04). Five of 8 adults whose households contained firearms took new action to limit access after injury prevention education, whereas none of the 7 firearm-owning families who did not receive injury prevention education took new action to limit firearm access. Similar patterns were seen for other means. Adults more often chose to lock up rather than dispose of lethal means. CONCLUSIONS: Injury prevention education should be provided to parents during child/adolescent emergency department mental health-related visits. Potential for violence prevention is real because parents do take new action to limit access to lethal means when means restriction education is provided.


Subject(s)
Emergency Service, Hospital , Parents/education , Suicide Prevention , Violence/prevention & control , Adolescent , Adult , Child , Female , Follow-Up Studies , Humans , Male , Outcome and Process Assessment, Health Care , Prospective Studies , Suicide/psychology , Violence/psychology , Wounds and Injuries/prevention & control , Wounds and Injuries/psychology
SELECTION OF CITATIONS
SEARCH DETAIL
...